Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 38Recruiting 21Terminated 9Active not recruiting 9Unknown 7Withdrawn 6Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 4Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Breast Neoplasms 430Neoplasms 284Carcinoma, Non-Small-Cell Lung 266Colorectal Neoplasms 228Lung Neoplasms 173Prostatic Neoplasms 171Carcinoma, Hepatocellular 156Stomach Neoplasms 129Leukemia, Myeloid, Acute 118Pancreatic Neoplasms 115Multiple Myeloma 105Recurrence 96Uterine Cervical Neoplasms 91Squamous Cell Carcinoma of Head and Neck 88Neoplasm Metastasis 87Rectal Neoplasms 85Ovarian Neoplasms 77Triple Negative Breast Neoplasms 75Small Cell Lung Carcinoma 72Head and Neck Neoplasms 68Brain Neoplasms 68Esophageal Neoplasms 64Glioblastoma 63Colonic Neoplasms 60Endometrial Neoplasms 58Melanoma 54Hematologic Neoplasms 53Motor Activity 50Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Nasopharyngeal Carcinoma 46

Interventions

anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Interventional × Pheochromocytoma × Clear all
NCT06429397 2025-04-29

Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma

Sun Yat-sen University

Phase 2 Not yet recruiting
22 enrolled
Endocrine

Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡